Johnson & Johnson (JNJ) Q3 2024 earnings summary

Executive summary

• Q3 2024 reported sales grew 5.2% year-over-year to $22.5B, with operational growth of 6.3% and strong performance in both Innovative Medicine and MedTech segments, driven by new product launches and regulatory milestones.

• Net earnings from continuing operations were $2.7B, with diluted EPS at $1.11, down 34.3% year-over-year due to litigation and IPR&D expenses; adjusted EPS was $2.42, down 9.0%.

• Strategic acquisitions (Shockwave, V-Wave, Ambrx, Proteologix, NM26) accelerated portfolio shift to high-growth markets and boosted MedTech growth.

• Multiple pipeline advancements and regulatory approvals, including Rybrevant plus Lazcluze for lung cancer and Tremfya for ulcerative colitis; IDE submission for Ottava robotic system.

• Significant legal accruals for talc litigation, with a $5.0B charge in 2024 and a $12.0B reserve as of Q3; Red River Talc LLC filed for Chapter 11.

Financial highlights

• Q3 worldwide sales reached $22.5B, up 5.2% year-over-year; U.S. sales grew 7.6%, international sales 4.6% operationally.

• Net earnings from continuing operations were $2.7B; adjusted net earnings were $5.9B; adjusted EPS was $2.42, down 9% year-over-year, impacted by $1.25B IPR&D expense.

• Gross margin remained stable at 69.0% of sales; operating margin was 14.9% reported, 32.4% adjusted.

• Free cash flow YTD was ~$14B; ended Q3 with $20B in cash and $36B in debt; net debt at Q3 end was $15.5B.

• Effective tax rate was 19.3% in Q3 2024, up from 17.4% last year, driven by acquisitions and legislative changes.

Outlook and guidance

• Raised full-year 2024 adjusted operational sales growth guidance to 6.3%-6.8% (midpoint $89.6B); reported sales growth 5.1%-5.6%.

• Adjusted operational EPS guidance for 2024 is $9.91 at midpoint, reflecting acquisition-related dilution and improved performance.

• MedTech adjusted operational sales growth for 2024 expected closer to 5% due to Asia-Pacific headwinds.

• 2025 outlook includes continued growth in Innovative Medicine and MedTech, with biosimilar entry for Stelara in U.S. expected January 2025.

• Pillar Two global minimum tax expected to increase 2024 effective tax rate by 1.0–1.5% over 2023.